Pure Biologics S.A. Logo

Pure Biologics S.A.

Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pure Biologics S.A. is a biopharmaceutical company focused on the discovery and development of novel biological drugs and non-systemic therapies. The company utilizes its expertise in antibody and aptamer technologies to develop new therapeutic molecules. Its development portfolio primarily targets immuno-oncology and autoimmune diseases. A key element of its strategy is the focus on creating entirely new biological drugs, as opposed to generic or biosimilar alternatives, positioning itself as an innovator in the biotechnology sector.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 17:54
Share Issue/Capital Change
Rejestracja warrantów subskrypcyjnych imiennych serii C uprawniających do objęc…
Polish 798 bytes
2025-11-14 17:33
Regulatory News Service
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 01.07.2…
Polish 4.1 MB
2025-11-14 17:33
Regulatory News Service
Jednostkowy raport kwartalny Pure Biologics S.A. za 3Q 2025
Polish 1.5 MB
2025-10-27 16:14
Share Issue/Capital Change
Asymilacja akcji serii N Spółki z akcjami znajdującymi się w obrocie na rynku r…
Polish 1.5 KB
2025-10-27 14:05
Registration Form
Rejestracja akcji na okaziciela serii P1 w depozycie papierów wartościowych pro…
Polish 1.1 KB
2025-10-24 18:37
Share Issue/Capital Change
Dopuszczenie i warunkowe wprowadzenie do obrotu na rynku równoległym prowadzony…
Polish 1.5 KB
2025-10-22 11:37
Share Issue/Capital Change
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.2 KB
2025-10-21 17:52
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym…
Polish 1.3 KB
2025-10-21 17:04
Post-Annual General Meeting Information
Treść uchwał podjętych przez NWZ Pure Biologics S.A. w dniu 21.10.2025 r.
Polish 218.5 KB
2025-10-21 17:04
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Pure Biologics S.A…
Polish 775 bytes
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienie Filip Jeleń
Polish 75.8 KB
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienie ACRX Investments Limited
Polish 77.7 KB
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienia akcjonariuszy o zmianie stanu posiadania akcji Spółki - Content (…
Polish 765 bytes
2025-10-15 17:53
Registration Form
Tekst jednolity statutu Spółki
Polish 351.5 KB
2025-10-15 17:53
Registration Form
Rejestracja podwyższenia kapitału zakładowego i zmian statutu Spółki w rejestrz…
Polish 6.1 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pure Biologics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.